Greater diversity in drug supply and use is creating new challenges for drug policy and healthcare in Europe. This is among the issues highlighted today by the EU drugs agency (EMCDDA) as it launches its European Drug Report 2023: Trends and Developments in Brussels.
Based on data from 29 countries (EU 27, Türkiye and Norway), the report delivers the latest overview of the drug situation in Europe, exploring long-term trends and emerging threats. The comprehensive analysis covers drug use and supply as well as drug-related harms and responses to them.
The depth and scope of the analysis has been considerably expanded this year, with a wider range of topics covered and in greater detail. For the first time ever, the report is delivered in a new modular, digital-first format, offering innovative ways to access and interact with the content. The resource is designed to be read across a range of devices (PCs, mobiles, tablets) and is available in 25 EU languages.
Over 100 interactive graphics complement the analysis, while dedicated interactive dashboards allow users to visualise data and trends at European and national level. Data journalists and researchers will be able to access the underlying data for easier sharing and re-use. Accompanying the report is the 2023 Statistical Bulletin containing national datasets.